|
Dr. Johnson, with over 30 years of experience in government and industry, has worked in all aspects of cancer drug discovery/development. This experience ranges from target validation, through screening technologies, basic research on mechanisms of drug action, assessment of efficacy in preclinical tumor models, to clinical development plans and regulatory strategies. He has put many drugs into clinical development and is credited with bringing topotecan to market.
After receiving a degree in Pharmacology, Dr. Johnson worked at the National Cancer Institute, at Arthur D Little, and for 20 years at GlaxoSmithKline / SmithKline Beecham Pharmaceuticals. He now consults for many pharmaceutical companies, both large and small, provides venture capital groups with assessment of investment opportunities and serves on the Scientific Advisory Boards of five other biotechnology companies. | 